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Abstract
The placenta is a unique temporary organ essential for growth of the fetus, which deter-
mines the success of pregnancy. Its originality relies on a combination of nutritive, endo-
crine and immunological functions that control maternal immune tolerance to fetus. In 
the present chapter, we review gene expression programs of placenta from placenta tis-
sue to isolated cells using high throughput transcriptomic approach. Beside trophoblasts, 
we focused on immune cells including macrophages, dendritic cells and mast cells. From 
the gene expression signatures, we identify key pathways for the different trimesters of 
the normal pregnancy and pathological alterations including preeclampsia and gesta-
tional diabetes mellitus.
Keywords: placenta, pregnancy, preeclampsia, gestational diabetes mellitus,  
immune cells, gene regulation
1. Introduction
The placenta is a unique temporary organ and the central regulator of maternal-fetal environ-
ment [1]. It is a complex organ that needs to adapt constantly to maternal and fetal require-
ments during the progression of the pregnancy. The placenta is composed of several varieties 
of cells including trophoblasts, mesenchymal and endothelial cells and immune cells [2]. It is 
essential for materno-fetal exchange enabling the transfer of regulatory molecules to the fetus 
and fetal molecules to the maternal circulation [3]. The placenta is also involved in hormonal 
regulation [4, 5] and immunological defense of mother [6] and fetus [7]. The placenta syn-
thetizes and secretes large number of molecules necessary for its development, metabolism 
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of mother and fetus growth [8]. These factors including placental hormones and growth fac-
tors lead to the regulation of gene expression critical for placenta plasticity and functions 
including angiogenesis, immune response, decidua invasion, endocrine regulation and fetal 
nutrition and growth [9].
The investigation of a complex organ such as placenta requires an approach without a priori 
that can be provided by high throughput methods such as microarray, ribonucleic acid-
sequencing (RNA-Seq) and/or quantitative reverse transcription-polymerase chain reaction 
(qRT-PCR) technologies, which markedly changed our analysis of tissue physiology and 
pathophysiology. This field is expanding since the investigation of keywords including pla-
centa, transcriptomic and gene expression on PubMed database revealed a progression of the 
number of publications per years from 1 in 2001 to 55 in 2017 (Figure 1). The transcriptomic 
studies have enabled identification of specific genes involved in the progression of the gesta-
tion and the outcome of complications. These gene signatures may be used as new biomarkers 
for maternal and fetal complications of pregnancy.
In this chapter, we will review the literature focusing on the gene expression profiling of 
placenta tissue and isolated cells during the progression of the gestation and pathological 
pregnancies.
Figure 1. Number of publications associated with “placenta, transcriptome and gene expression”.
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2. Placenta transcriptome in normal pregnancy
2.1. Gene expression and anatomic organization of placenta
Human placenta is a feto-maternal organ composed of the fetal part (also known as chorion) 
and the maternal part (also known as decidua). The chorion is composed of trophoblasts, 
cytotrophoblasts and syncytiotrophoblasts, whereas the decidua contains enlarged endome-
trial stromal cells (epithelium) and leukocytes populations, thus suggesting that these two 
parts of placenta tissue are functionally different.
Few studies have investigated the transcriptomic profile of the different areas of the pla-
centa tissue (Table 1). As shown in Table 1, two studies have investigated gene expression 
in amnion, chorion, decidua and villus parenchyma of at term placenta using microarray or 
RNA-sequencing. A core of gene expression patterns was observed in the different areas of 
the placenta; they are related to histology categories [10]. Microarray analysis revealed major 
differences among amnion, chorion and villus parenchyma. It showed that the gene encoding 
Species Placenta and 
gestational age
Technique Results References
Human At term placentas 
(amnion, chorion, 
umbilical cord 
and section 
of villus 
parenchyma)
Microarray • Differentially modulated genes are associated 
with placental trophoblast secretion, signal 
transduction, metabolism, immune regulation, 
cell adhesion and structure
• Inter-individual differences are observed in gene 
expression between the mother and the fetal 
section of the placenta
• The expression of a set of genes is related to the 
sex of the fetus
[10]
Human At term placenta 
(amnion, chorion 
and decidua 
part)
RNA-
sequencing
• 938, 865 and 944 genes are modulated in amnion, 
chorion and decidua tissues, respectively
• 216 genes were commonly modulated among the 
three placenta tissues
• Common genes were associated with placenta 
abnormalities including prolactin receptor, 
insulin-like growth factor 2 and a set of genes 
enriched with interleukin-1 pathway
• Amnion: genes associated with cell adhesion and 
epidermal cell differentiation
• Chorion: genes associated with angiogenesis, cell 
proliferation and Wnt receptor signaling
• Decidua: genes associated with female preg-
nancy and wound healing
[11]
Table 1. Transcriptomic analysis of tissue component of the placenta.
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Mucin 1 (MUC1) gene was strongly expressed in the amnion, whereas a cluster of up-mod-
ulated genes associated with signal transduction, cell differentiation and immunity catego-
ries was found in chorion. Among these genes, tissue remodeling genes, genes induced by 
interferon and major histocompatibility complex (MHC) genes were strongly up-modulated, 
suggesting a role for chorion in the plasticity and the immune tolerance of the placenta during 
pregnancy. Hypoxia-inducible factor (HIF)-1α, a transcription factor known to induce tran-
scription of genes involved in glycolysis, erythropoiesis and angiogenesis [12], was expressed 
at low level in villus sections of placenta. In contrast, HIF-1α was up-modulated in amnion 
chorion and decidua [11]. It is likely that these discrepancies are related to exposition to dif-
ferent gradients of oxygen, which modulate HIF-1α expression.
Although these studies based on at term placentas are limited, they suggest that distinct tis-
sue transcriptional programs exist in placenta. In addition, some inter-individual variations 
of the placenta structures have been observed during the second and the third trimester of 
the pregnancy [13]. Further investigations must include placentas at the different age of the 
gestation to precisely map gene expression in different areas of placenta during pregnancy.
2.2. Evolution of placenta gene expression during pregnancy
During pregnancy, the placenta gene expression is continuously modulated to adapt immune 
response to tolerance necessity and to modify metabolism according to pregnancy require-
ment. Hence, the early stages of the pregnancy are characterized by trophoblast invasion, 
which leads to placentation. During the mid-gestation, the placenta adapts its gene expres-
sion to maintain the fetal growth and the organ development. Finally, during the third trimes-
ter, placenta must provide enough nutriments for the growing of the fetus. Some evidence 
suggests that preterm birth is related to changes in gene expression during pregnancy [14].
The evolution of placenta gene expression during the different gestational stages is summa-
rized in Table 2. The five studies investigated gene expression at different gestational ages 
in humans and mice. They identify common gene pathways involved in cell differentiation, 
immune response and angiogenesis (Table 2). In first trimester, the few genes that are found 
modulated are strongly involved in cell proliferation vascular development and angiogen-
esis. At mid-gestation several genes associated with cycle control, including cyclin family, are 
found up-modulated [17, 19]. There is an enrichment in gene ontology (GO) terms related to 
growth of the placenta, the set-up and the maturation of villous with blood vessels during 
first and second trimester as compared with third trimester [15, 20]. In addition, GO terms 
for cell differentiation and communication are also observed and are related to the organi-
zation of placenta structure and plasticity [21]. All studies observed a major change in the 
gene expression pattern at the end of the pregnancy. The third trimester is associated with 
the over-expression of genes involved in apoptosis, oxidative stress response and inflamma-
tory process [17, 18], whereas the second and third trimesters share the up-modulation of 
genes associated with immune response. It has been recently shown that the gene expres-
sion program of placentas at the third trimester exhibits activation of the immune response 
and an increase of oxygen-rich maternal blood in placenta, which reflect labor and delivery 
route [22, 23].
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Species Placenta and 
gestational 
age
Technique Results References
Human First trimester
(45–59 days)
Second 
trimester
(109–115 days)
Microarray • 500 genes common to the 1st and 2nd trimesters
• 836 genes specific to the 1st trimester
• 264 genes specific to the 2nd trimester
• 1st or 2nd trimesters versus term: cell division, mitosis, 
DNA metabolism, pregnancy, response to chemical, 
immune response and regulation of cell cycle
• Genes included in gestational regulation of the Wnt 
pathway
[15]
Human First trimester
(6–7 weeks)
Third 
trimester
(279 days)
qRT-PCR • Cysteine dioxygenase (CDO) mRNA is up-modulated in at 
term placentas compared to 1st trimester placentas
[16]
Human First
(9–12 weeks)
Third 
trimester
Microarray • 7519 genes differentially expressed between 1st and 3rd 
trimesters
• Biological processes up-regulated in 1st trimester: cell 
proliferation, cell differentiation and angiogenesis
• Biological processes up-modulated in 3rd trimester: cell 
surface receptor-mediated signal transduction, G-protein 
mediated signaling, ion transport, neuronal activities and 
chemosensory perception
• 3D separation observed for 17 imprinted genes of 1st and 
3rd trimester placentas, suggesting epigenetic modifications
[17]
Human Second
(14–16 and 
18–19, 21, 
23–24 weeks) 
and third 
trimesters
(37–40 weeks)
Microarray • Little changes on gene expression observed during 14 to 
24 weeks
• 418 genes differentially modulated at the third trimester 
(37–40 weeks) compared to mid gestation (14–24 weeks)
• These genes are involved in differentiation, motility, 
transcription, immunity, angiogenesis, extracellular matrix 
dissolution and lipid metabolism
[18]
Mice Embryonic 
day 10.5, 12.5, 
15.5 and 17.5
Microarray • 599 genes differentially modulated
• Up-regulation of genes associated with angiogenesis fatty 
acid metabolism and transport for E 10.5 compared to E 12.5
• Up-regulation of genes associated with hormonal control 
and ribosomal proteins for E 12.5 compared to E 10.5
• Up-regulation of genes associated with cell cycle and RNA 
metabolism for E 12.5 compared to E 15.5
• Up-regulation of genes associated with cellular transport for 
E 15.5 compared to E 12.5
• Up-regulation of genes associated with cell cycle control 
and RNA metabolism for E 17.5 compared to E 15.5
[19]
Table 2. Transcriptomic analysis of uncomplicated normal pregnancies at different ages of pregnancy.
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2.3. Term labor and gene expression
The molecular mechanisms regulating the initiation of labor are still poorly understood. The 
key role of genes involved in prostaglandin synthesis and inflammatory responses in cervix, 
myometrium and chorio-membranes has been reported in laboring women as compared with 
non-laboring women [24]. Table 3 summarized the studies evaluating placenta gene expres-
sion from preterm versus term labor with vaginal or cesarean deliveries. The commonly 
modulated genes are involved in immune response and apoptosis. Oros et al. showed a bal-
ance of immune modulators with an increased expression of tumor necrosis factor (TNF) and 
interleukin (IL)-6 and a decrease in interferon (IFN)-γ expression [26]. These results are likely 
related with cytokine production of at term placentas [30] and M1 polarization shift of mac-
rophages [31]. Another study showed that gene expression associated with oxidative stress 
is elevated [25]. It has been previously observed that oxidative stress in placenta explants 
Species Placenta and 
gestational age
Technique Results References
Human 5–10 min before 
delivery (preterm 
labor or not)
Microarray • Functional ontology analysis response to stress, 
cell surface receptor-linked signal transduction, 
regulation of transcription, immune system 
process, blood vessel development, death, 
cell-adhesion, cell-cell signaling, coagulation and 
oxygen and reactive oxygen species metabolism 
process
[25]
Human Preterm 
(26–36 weeks)
Term (>37 weeks) 
all with suspicion 
of preterm labor
qRT-PCR • Increased expression of TNF, IL-6 and PGF
• Decreased expression of IFN-γ and VEGFR1
• Term delivery after suspicion of preterm labor 
shows decreased VEGFA
• Preterm delivery after suspicion of preterm labor 
shows decreased VEGFB
[26]
Human Term (38–
42 weeks) with 
vaginal delivery 
or cesarean
Microarray • Up-regulated genes in placenta by labor are 
involved in angiogenic regulators, immune 
response, inflammatory response and apoptosis
[27]
Human Term (34 weeks) 
with vaginal 
(laboring) 
delivery or 
cesarean 
(non-laboring)
Microarray • 92 genes down- and 94 up-regulated genes in 
laboring placentas compared to no-laboring 
placentas
• FOS, FOSb and GNGT1 are down-modulated 
in laboring placentas compared to non-laboring 
placentas
[28]
Human Term and term 
nonlaboring 
cesarean 
deliveries
Microarray • Labor is associated with up-modulated expression 
of MMP-1 gene in chorionic villus tissue
• Genes involved in the extracellular matrix 
homeostasis are up-modulated such as fibronectin 
1 and collagen XVII
[29]
Table 3. Transcriptomic analysis of uncomplicated pregnancies from preterm or term labor.
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and production of inflammatory cytokines are related [25]. The TNF levels are elevated 
during labor, suggesting that TNF may be a biomarker of preterm labor [32, 33]. Based on 
gene expression in placenta, epidemiological analysis suggested a genetic predisposition to 
spontaneous preterm labor and preterm birth [34]. Nevertheless, additional investigation of 
transcriptomic analyses must be necessary to better understand the role of gene expression 
in term labor.
2.4. Placenta microRNAs in pregnancy
MicroRNAs are small non-coding 20–24 nucleotides that target and regulate numerous genes 
[35]. They are expressed by tissues and cells but can also circulate in blood. They can be used 
as biomarkers [36]. It has been reported that more than 500 microRNAs are produced by the 
human placenta and a part of them are placenta specific [37]. Their expression varies with the 
gestational stages; 191 microRNAs are differentially modulated in placentas from first versus 
third trimester [38]. During the first trimester, microRNAs are associated with angiogenesis, 
anti-apoptosis and oncogenesis categories, whereas microRNAs from third trimester are 
related to cell differentiation and tumor suppression categories. Luo et al. found that miR-
378a-5p is up-modulated in first and second trimesters but not in third trimester in placenta 
tissue [39]. The variations of microRNAs expression during different gestational ages suggest 
that they may regulate specific functions during pregnancy. However, the studies investigat-
ing microRNAs in total tissue in normal pregnancy are scarce and further investigations are 
necessary to better characterize microRNA signature and their temporal expression pattern in 
the placenta at different ages of gestation.
3. Placenta transcriptome in pathological pregnancy
The alteration of gene expression pattern in placenta tissue may reflect metabolic disorders 
associated with pregnancy such as gestational diabetes mellitus or pathologies that compro-
mise pregnancy success such as preeclampsia [40]. We will summarize main findings reported 
in preeclampsia and gestational diabetes mellitus that represent the two pathologies mainly 
investigated by transcriptomic analyses.
3.1. Preeclampsia
Preeclampsia is a severe placenta disease that occurs in 3–5% of pregnant women and is a 
source of complications for mother and fetus [41–43]. The preeclampsia is initiated at the time 
of trophoblast invasion and remodeling of the spiral arteries during the first and early second 
trimester of pregnancy [41, 44, 45]. Initial studies have shown that elevated levels of vari-
ous placental proteins in maternal blood such as FLT1 (fms-related tyrosin kinase 1), sENG 
(soluble engolin) and PGF (placental growth factor) in early pregnancy may be predictive of 
preeclampsia development [46] but the presence of false negative rates limits their clinical use 
[47]. The use of high throughput methods such as microarray is likely useful to identify new 
biomarkers and potential therapeutic targets. Table 4 summarizes transcriptional studies of 
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Species Placenta and 
gestational age
Technique Results References
Human At term preeclampsia 
or healthy
Microarray • HLA-DRB1, but not HLA-A RQ and CSTM2 
RQ genes, is up-regulated in placenta tissue 
from women with pre-eclampsia
• HLA-A and HLA-DRB1 expression are related 
to the reduction of birthweight but not placenta 
weight
[48]
Human At term preeclampsia 
or healthy
Microarray • Increased glycogen phosphorylase gene in 
preeclampsia group compared to controls
[49]
Human At term (>37 weeks) 
preeclampsia or 
healthy
Microarray • Among 368 regulated genes in preeclampsia 
group compared to controls, 35% present an 
expression higher than 2.0
• Up-regulated genes are associated with cell-
cycle or apoptosis functions
• Up-regulation of immune-system activation-
related genes
• No differences of MHC complex in the two 
groups
[50]
Human Term (32–40 weeks) Microarray • A few numbers of genes (21) are differentially 
expressed
• Genes involved in transcriptional regulation, 
vaso-regulative pathways. Hypothetical protein 
and gene sequences with unknown functions
[51]
Human Placenta with 
preeclampsia or 
from healthy donors 
(253–273 days)
Microarray • Genes involved in cell proliferation, immune 
regulation, lipid biosynthesis, protein biosyn-
thesis and transport, signal transduction are 
up-modulated
• Genes previously involved in preeclampsia 
such as Flt-1, leptin, HTRA1 and SIGLEC6 are 
modulated
[52]
Human Placenta with 
preeclampsia or 
from healthy donors 
(<32 weeks)
Microarray • Modulation of genes involved in cell adhesion-
related protein, obesity-related protein, tran-
scription factor, immunological factor, protease 
inhibitor, neuro-mediator, endocrine-related 
protein, oncogenic factor and growth factor
• Obese gene is the most up-modulated gene
[53]
Human Placenta with 
preeclampsia, 
increased vascular 
resistance (notch) or 
from healthy donors
Microarray • 148 genes are altered
• Up-modulated genes associated with 
chemotaxis, NF-kappa B pathway are found in 
preeclampsia group compared to notch
• Down-modulated genes associated with 
antigen processing and presentation (human 
leukocyte antigen B) are found in preeclampsia 
group compared to notch
• Results suggest that progression of pre-
eclampsia from notching is dependent of the 
development of inflammation
[54]
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Species Placenta and 
gestational age
Technique Results References
Human Placenta with 
preeclampsia or 
from healthy donors 
(39 weeks)
RNA-Seq • 53 differently expressed genes are modulated
• Perturbation of pathways involved in vascular 
function and immunological balance in 
preeclampsia group
• Some identified-genes have been previously 
reported (e.g. leptin) or not previously associ-
ated with preeclampsia
[55]
Human Placenta with 
preeclampsia or 
from healthy donors 
(35–39 weeks)
Microarray • 58 genes are modulated and associated with 
immune system, inflammation, oxidative 
stress, signaling, growth and development 
pathways
• Some genes identified have been previ-
ously reported (leptin) or not previously 
associated with preeclampsia (CYP11A and 
CDKN1C)
[56]
Human Placenta with 
preeclampsia 
(31–39 weeks), 
preterm labor 
(24–33 weeks) or 
from healthy donors 
(37–39 weeks)
Microarray • 20 miRNAs and 120 mRNAs are differentially 
modulated in preeclampsia and preterm group 
compared to healthy donors
• Functional analysis shows a common activity 
of these genes associated to cellular activities
[57]
Human Placenta with 
preeclampsia 
(mean 34.2 weeks), 
with small for 
gestational age 
(mean 34.5 weeks) 
or both (mean 
33.9 weeks)
Microarray • No significant difference between preeclampsia 
and small-for gestational-age groups
• Increased anti-angiogenic gene expressions are 
observed
[58]
Human Placenta with 
preeclampsia or from 
healthy donors (mean 
37.5 and 39.8 weeks, 
respectively)
Microarray • Differentially expressed genes associated with 
inflammation, immune regulation and cell 
motivity are found
[59]
Human Placenta with 
preeclampsia 
or from healthy 
donors (mean 34.6 
and 38.6 weeks, 
respectively)
Microarray • 896 differentially expressed genes are found
• Up-regulation of HTRA4, LHB and β-hCG
• Decreased of NOX4 gene
[60]
Human Placenta with 
preeclampsia or 
from healthy donors 
(34–37 weeks)
Microarray • 2109 differentially expressed genes are found
• Down-modulation of CD4
• Up-regulation of LEP, FLT1, PAPPA2, INHA, 
SIAE and ENG
[61]
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placenta from women with preeclampsia. Most studies use at term placentas and report a 
number of modulated genes varying from 20 to more than 2000.
Among the up-modulated genes, those associated with the regulation of the immune response 
are most frequently reported in transcriptomic analysis of preeclampsia placentas (Table 4). 
These findings may be related to the up-regulated gene expression profile of circulating cells 
from pregnant women with preeclampsia [65–67] and to the observation of increased levels 
of inflammatory cytokines including IL-6, IL-8 and TNF [68, 69]. Indeed, using microarray 
approach on blood samples, we observed a specific transcriptional signature of genes up-
modulated in severe preeclampsia including genes associated with ribosome and comple-
ment functions [67]. In addition, we had identified VSIG4 (V-set and immunoglobulin domain 
containing 4) as a biomarker of severe preeclampsia.
Among genes associated with immune response, three studies reported the modulation of 
human leukocyte antigen (HLA) genes [48, 54, 59]. HLA-A, HLA-B and HLA-DRB1 are up-
modulated in placentas from preeclampsia as compared to control group. The molecules, 
HLA-A and HLA-DRB1 have been associated with preeclampsia outcome [48, 70, 71] and 
have been related to reduced birth weight but not to placenta weight. Clinical observations 
show that both birth weight [72] and placenta weight [73] are decreased in pregnant women 
with preeclampsia.
Species Placenta and 
gestational age
Technique Results References
Human At term placenta with 
preeclampsia or from 
healthy donors
Microarray • 213 and 82 genes are found up- and down-
modulated, respectively
• Differentially expressed genes are observed 
between early and late onset preeclampsia
• Up-regulation of FLT1, PAPPA2, CGB5, LEP 
and INHBA
• Down-modulation of PDGFD, BHLHB3 and 
BMP5
[62]
Human Variable Meta-gene 
analysis on 
microarray 
experiment 
in published 
studies
• Differential expression of autophagy-associated 
genes is found in microarray datasets from 
separate published studies
[63]
Human Term Meta-gene 
analysis on 
microarray 
experiment 
in published 
studies
• The most highly affected pathways in 
preeclampsia placenta are Wnt, ErbB, PPAR, 
Hedgehog signaling pathways, mRNA 
surveillance pathway and ubiquitin mediated 
proteolysis.
• Identification of specific genes for preeclamp-
sia: LEP, HTRA4, SPAG4, LHB, TREM1, FSTL3, 
CGB, INHA, PROCR and LTF genes
[64]
Table 4. Transcriptomic analysis of pregnancy with preeclampsia.
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Gene associated with hypoxia and oxidative stress are frequently found in placenta from 
women with preeclampsia. The placental hypoxia associated to preeclampsia is due to shallow 
implantation, impaired trophoblast invasion or vascularization of placenta arteries [40, 74]. 
The hypoxia leads to low birth weight and newborn diseases [75]. The gene encoding leptin 
has emerged as a potential biomarker of preeclamptic placentas from transcriptomic analyses 
[52, 56, 76]. This gene is known to be up-modulated in placenta from patients who experi-
ence chronic hypoxic ischemia [77]. Other genes involved in hypoxia are down- modulated in 
preeclampsia: this is the case for the gene encoding a glutathione reductase, an antioxidant 
protein, whereas the gene encoding the thioredoxin peroxidase is up-regulated [78]. In con-
trast, Zhang et al. found no modulation of genes encoding enzymes involved in oxidative 
stress as compared to controls [79].
The transcription analysis enables the identification of several up-modulated genes includ-
ing genes involved in apoptosis processes [50], activin-A, inhibin A [80], soluble sENG [61], 
soluble sFlt-1 [61] and placental growth factor PGF [81]. In these studies, three angiogenic 
genes are found differently expressed: they include sFLT1 (also known as vascular endo-
thelial growth factor, VEGF), PGF and sENG that are up-modulated in preeclampsia and 
associated with severe preeclampsia [61, 62, 82, 83]. In a case-control clinical study, the level 
of sFLT1 increases and that of PGF decreases during normal pregnancy; this response is 
more pronounced in women who develop preeclampsia [46]. Thus, it has been proposed 
that sFLT1 could be used as biomarker for predicting the development of preeclampsia [84]. 
However, these genes are not found in all transcriptomic studies of preeclamptic placentas 
[85]. This discrepancy may be explained by the clinical heterogeneity of preeclampsia, pla-
centa sampling sites, gestational weeks, sex of the child, labor and the method of delivery. 
These parameters restrict the use of these genes as biomarkers for diagnosis or prognosis of 
preeclampsia.
3.2. Gestational diabetes mellitus
Placenta is an endocrine organ that provides glucose to fetus. A pathological state of insulin 
resistance leading to glucose intolerance is called gestational diabetes mellitus (GDM) [86]. The 
mother may develop hemorrhage, hypertension, infection, difficulty in labor and increased 
risk of mortality [87]. The placentas from GDM patients exhibit histological alterations and 
elevation of its size and weight at third trimester. This may be due to insufficient production 
of placental hormones [88]. To better understand the role of placenta in the development 
of GDM, transcriptomic analyses of placenta from pregnant women with a GDM or mice 
model of diabetes have been conducted in some studies (Table 5). Few genes are differentially 
modulated and they are predominantly related to extracellular matrix remodeling, immune 
response and regulation of apoptosis categories.
Among the immune response category, genes such as TNF are up-modulated. TNF is 
known to be involved in insulin resistance, obesity and diabetes [95, 96]. Although TNF 
levels are increased in GDM and type 1 diabetes [97], no relation was found between pla-
centa TNF mRNA amounts and the levels of this cytokine in maternal blood with GDM 
[98–100].
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Species Placenta and 
gestational 
age
Transcriptomic 
technique
Results References
Mouse
(Streptozotocin 
induced-diabetes)
E 10.5 Microarray • 158 genes are modulated in diabetic 
placentas compared to controls (47% 
down-and 54% up-modulated genes)
• Functional category: extracellular 
matrix, hormones, cell surface receptor, 
signal transduction, transcription fac-
tors, metabolism, channel, cytoskeleton 
and RNA binding
• Diabetes-induced molecular changes 
and abnormal differentiation of cells, 
modification of growth and junctional 
zone and labyrinth
[89]
Human Placenta with 
GDM
(38 weeks)
Microarray • Increased expression of genes 
involved in markers and mediators of 
inflammation
• Increased expression of genes involved 
in stress-activated and inflammatory 
responses
• Increased expression of genes encoding 
interleukins, leptin and TNF receptors
• Gene modulation is associated with 
extracellular matrix component and 
angiogenic activators
[90]
Human Placenta with 
GDM or from 
healthy donors
(mean 37.7–
38.4 weeks)
Microarray • 66 genes are up-modulated in GDM 
placentas
• Modulated genes are associated with 
cell functions (activation), immune 
response, organ development and 
regulation of cell death
• Modulated genes including LEP, 
CEBPA and MIF have been previously 
described
• Up-modulation of AQP3, LEP, FLT1, 
ADFP, CEBPA and MIF genes
• AQP3 is a new gene associated with 
GDM outcome
[91]
Mouse
(60% calories-
by-fat diet 
induced-diabetes)
E 12.5 nCounter 
nanostring
• Altered gene expression in the fetal 
brain
• GDM mice present repressed genes 
associated with neuro-developmental, 
cholinergic signaling, IFN/antiviral 
response, growth, cell cycle regulation 
and apoptosis
• GDM mice present increased expression 
of genes associated with inflammation
[92]
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Transcriptional studies reveal strong association of leptin (LEP) with GDM [90, 101, 102]. LEP 
is up-modulated in placenta and could be a cause or a result of glucose uptake in placentas 
from women with GDM [102, 103]. Elevated circulating levels of LEP are found in GDM but 
LEP is also found in others pathological pregnancies such as preeclampsia. The changes in 
LEP concentration are associated with the modulation of cytokines such as TNF [102].
Finally, common modulated genes are found in transcriptome analyses of placental gene 
expression in term pregnancy complications, suggesting that they could be associated more to 
a dysfunction of the placenta than to a specific complication. As examples, FLT1 (fms-related 
tyrosine kinase 1) or PAPPA2 (Pappalysin-2) are commonly modulated in placenta disorders 
and could be used as biomarkers.
3.3. miRNAs in complicated pregnancy
Some investigations highlight dysregulation of microRNAs in preeclampsia and GDM, suggest-
ing their role in pathological pregnancies [104]. In preeclampsia, the upregulation of miR-210, 
miR-20b, miR-29b, miR-16, miR-155 and miR-675 is associated with angiogenesis and tropho-
blast invasion [44, 105–110]. In contrast, down-modulation of miR-378a-5p, miR-376 and miR-195 
is related to the promotion of trophoblast invasion and proliferation [39, 111]. However, some 
discrepancies are observed according to transcriptomic studies. For example, several studies 
showed that miR-210 represents the most up-regulated microRNAs in preeclampsia, whereas 
other studies found no change in placenta from preeclampsia compared to healthy donors [57].
Species Placenta and 
gestational 
age
Transcriptomic 
technique
Results References
Human At term 
placenta with 
GDM or from 
healthy donors
Microarray • Up-regulation of miR-508-3p and down-
modulation of miR-27a, miR-9, miR-137, 
miR-92a, miR-33a, miR-30d, miR-362-5p 
and miR-502-5p
• This gene signature targets EGFR, PI3K 
and AKT genes involved in placental 
development and fetal growth
[93]
Human Placenta with 
GDM or from 
healthy donors
(38 weeks)
Microarray • 435 genes are modulated
• 18.5% of modulated genes are involved 
in stress-activated and inflammatory 
responses
• Up-regulation of interleukins (IL-1R), 
leptin, and TNF receptors
[90]
Human Placenta with 
GDM
(23–41 weeks)
Microarray • 243 genes present an altered expression
• TNF, IL-1β, LEP, IFN-γ and HLA-G are 
differentially modulated
• Gene modulation is associated with 
cytokine-cytokine receptor interaction
[94]
Table 5. Transcriptomic analysis of pregnancy with gestational diabetes mellitus.
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Altered circulating levels of specific microRNAs have been reported in compromised preg-
nancies. For example, the low detection of miR-376c level in blood of 16–18 weeks preg-
nant women is related with the outcome of preeclampsia [112]. In similar conditions, three 
miRNAs, including miR-132, miR-29a and miR-222, are decreased in blood from women at 
16–19 gestational weeks who were diagnosed a GDM at 25–28 weeks of gestation [113]. Thus, 
despite the promising perspectives to use microRNAs in diagnosis of complicated pregnan-
cies, future studies are needed to provide a proof of concept.
4. Gene expression of placental immune cells
Beside the investigation of gene expression in whole placenta, several studies investigated 
transcriptomic profiles of isolated placental cells including immune and nonimmune cells. We 
focused here only on immune cells. Placental immune cells are necessary for development of 
the placenta bed and the semi-allogeneic tolerance of the fetal-placental unit. In addition, they 
are involved in the regulation of trophoblast invasion, angiogenesis and spiral artery remod-
eling. The distribution of immune placental cells is markedly distinct from that of circulating 
immune cells: NK cells and macrophages are found at high density, whereas lymphocytes, 
dendritic cells and mast cells are less represented. Therefore, we studied the transcriptomic 
response of macrophages, dendritic cells and mast cells.
4.1. Macrophages
Placental macrophages include decidual and Hofbauer cells from decidua (basalis) or villous 
stroma, respectively. They are the most abundant cells that persist throughout pregnancy 
[114, 115]. They play a central role in maintaining a homeostasis during pregnancy by con-
trolling imbalance between anti- and pro-inflammatory features of placenta environment 
[116, 117]. Indeed, the pro-inflammatory (M1) polarization of macrophages or the prevention 
of M2 polarization (anti-inflammatory and/or immunoregulatory properties) leads to spon-
taneous abortion or miscarriage [118], inadequate remodeling of the uterine vessels during 
placentation and protection against infection [119].
4.1.1. First and second trimesters
After placentation, placental macrophages exhibit a M2 profile during the first and second 
trimesters. This M2 profile contributes to the anti-inflammatory environment of the first part 
of pregnancy and the prevention of the rejection of the fetus by maternal immune system 
[120]. The first study of gene expression pattern in human first trimester decidual macro-
phages was conducted in 2008 [121]. The authors identified 14,000 genes modulated in pla-
cental macrophages compared to blood monocytes. Genes involved in immunomodulation 
and remodeling categories are associated with M2 phenotype. Hence, the genes encoding 
CCL18, CD209, insulin-like growth factor-1 (IGF-1), mannose receptor c type (MRC)-1 and 
fibronectin-1 are up-modulated. Houser et al. investigated the polarization of macrophage 
subsets isolated from decidua from first trimester (6–12 weeks) [122]. They identified two 
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distinct macrophage subsets according to CD11c expression, namely CD11clow and CD11chigh 
subsets. Both subsets expressed two M2 markers, CD209 (DC-SIGN) and CD206 (mannose 
receptor). Genes involved in invasion, mobility, inflammatory process and lipid metabolism 
are enriched in the two subsets, but genes involved in antiapoptotic pathways are found 
only in CD11high macrophages. In contrast, CD11clow macrophages express genes involved in 
growth regulation and development, and extracellular communication. These findings are 
in agreement with those of Svensson et al. who found two macrophage subsets, ICAM-3high 
and ICAM-3low, in macrophages from first trimester (7–12 weeks) [123]. Both macrophage 
populations express genes and cytokines associated with M2 profile and are related to CD11c 
expression.
4.1.2. Third trimester (term placentas)
The third trimester is associated to a pro-inflammatory environment. This inflammatory state 
is due to the synchronization of immune-endocrine cross-talk, based on especially estrogens 
[124], which favors M1 polarization of macrophages [125]. Indeed, a low level of estradiol is 
sufficient to promote macrophage M1 polarization, as measured by the secretion of inflam-
matory cytokines such as IL-1β, IL-6 and TNF. The investigation of DNA of at term placenta 
macrophages reveals the methylation of inflammatory genes including TLR9, IL-1β, IL-12RB2, 
CD48 and FGR and the hypomethylation of M2 genes including CCL2, CCL13, CCL14 and 
CD209 [126]. Using microarray analysis, we previously investigated the polarization of mac-
rophages from at term placentas in comparison to macrophage-derived monocytes [127]. We 
did not find a polarization of at term placenta macrophages. Indeed, both M1 (CXCL9, EDN1, 
IL-15, IL-15RA and IL-2RA) and M2 (FN1, CTSC and CCL23) genes were up-modulated. 
Interestingly, we reported for the first time the ability of placental macrophages to formed 
multinuclear giant cells (MGCs). These MGCs present functional enrichment in genes associ-
ated with cytoskeleton reorganization and immune response. In addition, as observed in pla-
cental macrophages, MGCs are not polarized. Taking together, although the third trimester is 
associated with an inflammatory environment, the activation of placental macrophages does 
not reproduce the classical model of M1/M2 polarization.
4.1.3. Placenta macrophages in pathological pregnancy
Placental macrophages are likely associated with number of pregnancy complications. Here, 
we focused on three pathological conditions, preeclampsia, GDM and chorioamnionitis, in 
which the involvement of macrophages is documented [128] .
4.1.3.1. Preeclampsia
Although alterations of macrophages are suspected in preeclampsia, the studies of placenta 
macrophages during preeclampsia are controversial [116, 129]. Some studies reported a 
decreased [115, 130, 131] or an increased [132–135] number of placental macrophages. In 
addition, they produce inflammatory cytokines and anti-inflammatory cytokines [136, 137]. 
It has been also reported that the count of M2 macrophages is decreased in the decidua of 
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preeclamptic placentas [132]. The transcriptomic and protein expression of CD74, a HLA 
class II molecule, are decreased in placental macrophages of preeclampsia women. This 
down-regulation of CD74 interferes with trophoblast-macrophage cross-talk [138]. Prins et al. 
investigated macrophages in early decidua from women who later developed preeclampsia 
[139]. They observed an increased expression of CD68 mRNA, but decreased CD206/CD68 
mRNA ratio, suggesting that the number of M2 macrophages is affected before the onset of 
preeclampsia. This finding may be related to the increased number of M1 macrophages in 
preeclamptic placenta found by other authors [140]. A better comprehension of the rupture 
of the M1/M2 balance may provide insight into understanding of preeclampsia pathogenesis.
4.1.3.2. Gestational diabetes mellitus
The inflammation associated with GDM leads to macrophage infiltration into placenta, sug-
gesting a key role of these cells during this metabolic complication of pregnancy. The number 
of macrophages is increased in placentas from women with GDM as compared to normal 
pregnancy [141]. Placental macrophages, isolated from an experimental model of diabetes 
(rats receiving an injection of streptozotocin), change from M2 to M1 inflammatory profile 
under high glucose stimulation [142]. Similarly, isolated placental macrophages from dia-
betic women present a M1 or an atypical M2 profile [142]. Immunohistochemistry and PCR 
approaches show that the mRNA expression levels of TNF and IL-6 are higher in placentas 
from women with GDM than in controls, suggesting an inflammatory profile of placenta 
macrophages. Further studies are needed to define the role of inflammatory macrophages 
in GDM.
4.1.3.3. Chorioamnionitis
During pregnancy, placenta could be the target of infectious agents. The chorioamnionitis, 
mainly due to ascending polymicrobial infection, is a severe complication of the pregnancy 
leading to an acute inflammation of the membrane and chorion [143]. In human placenta, we 
observed a decreased number of macrophages expressing CD14, CD68 and CD163 in at term 
placentas from women with chorioamnionitis compared to placenta from normal pregnancies 
[127]. Our results are in agreement with other reports [144, 145]. In addition, isolated macro-
phages from placenta with chorioamnionitis exhibit an altered inflammatory response with 
decreased production of IL-10 [127]. Other reports describe a M2 profile of macrophages from 
chorioamnionitis placentas [146]. These findings underline the role of placenta macrophages 
in the control of infection in pregnant women.
4.2. Dendritic cells
Dendritic cells are found at the feto-maternal interface and in decidua basalis [147]. They 
represent approximately 2% of leukocytes from placenta and their number does not vary 
through gestation. Both mature dendritic cells (expressing CD83) and immature den-
dritic cells (expressing CD14 and DC-SIGN) have been identified in placenta tissue [148]. 
Placenta42
We previously isolated decidual dendritic cells from at term placentas of healthy women 
by combining negative selection with anti-CD14 antibodies and positive selection with anti-
CD11c antibodies [149]. We found that 1525 genes are differentially modulated with a specific 
transcriptional profile as compared to monocyte-derived dendritic cells. It mainly consists of 
the up- modulation of genes involved in immunomodulatory cytokines, estrogen and proges-
terone gene pathway. The investigation of gene expression programs in placenta dendritic 
cells is emerging and will require additional investigation to associate gene expression and 
dendritic cells subsets in normal and pathological pregnancy.
4.3. Mast cells
Mast cells are found in human placentas [150] and it has been reported that mast cells and 
their products, especially histamine, could participate in the placenta development. Indeed, 
histamine is involved in trophoblast invasion and growth [151] and the cross-talk with tro-
phoblasts via the expression of adhesion molecules by trophoblasts [152]. The alteration of 
these specific adhesion molecules is associated with the impairment of placenta invasion 
and the outcome of preeclampsia. A decreased number of mast cells have been reported in 
preeclampsia, GDM and intrauterine growth retardation [151, 153]. To our knowledge, no 
data about gene expression in placenta mast cells has been published. We isolated placenta 
mast cells from at term women using positive selection with CD117 and IgE antibodies. In a 
comparative study with a mast cell line (human mast cells, HMC-1.2), we found that a large 
number of genes are up-modulated in placenta mast cells. The functional analysis reveals 
an enrichment with three categories, FcεRI signaling, immune response and reproduction 
processes. In this latter category, we identified specific genes of Wnt pathway and a set of 
genes involved in the response to estrogen and progesterone (manuscript in preparation). 
These preliminary results highlight the originality of placenta mast cells among placenta 
innate immune cells.
4.4. Common transcriptomic signature of macrophages, dendritic cells and 
mast cells
To identify a common signature of these three placenta immune cells, we performed a retro-
analysis of microarray data deposited in Gene Expression Omnibus at the National Center 
for Biotechnology Information. We evaluated the transcriptomic signatures of macrophages, 
dendritic cells and mast cells from at term placentas of healthy women and compared them 
to those of monocytes, monocyte-derived dendritic cells and the cell line HMC-1, respec-
tively. As depicted in Figure 2A, the hierarchical clustering reveals two major branches 
that distinguish cells of placenta origin from the others (ANOVA, p < 0.001). Focusing on 
common modulated genes, we observed that 479 (Figure 2B) and 5671 (Figure 2C) genes 
are up- and down-regulated, respectively. Interestingly, 45% of down-modulated genes 
are associated with pregnancy versus 10% of up-modulated genes. Thus, these data sug-
gest that innate immune cells express a core of genes that reflect the influence of placenta 
microenvironment.
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Figure 2. Transcriptomic analysis of dendritic cells, macrophages and mast cells from placenta tissue compared 
to controls including monocytes-derived dendritic cells, monocytes-derived macrophages and HMC-1 cell line, 
respectively. (A) Hierarchical clustering of placental cells showing the up- (red) and down- (green) modulated genes. 
Venn diagrams were realized to show the number of (B) up- and (C) down-modulated genes in common from dendritic 
cells (green), macrophages (blue) and mast cells (gray) from placenta.
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5. Conclusion
Transcriptional analysis of placenta reveals the modulation of a very large number of genes 
and pathways, allowing a better understanding of tissue and cell mechanisms of normal and 
pathological pregnancy. The development of RNA-Seq, with a better genomic coverage and 
more sensitivity than microarray, and single cell technology will permit promises to detect 
genes with low expression level and to reveal differential new gene expression for normal 
and complicated pregnancies. Thus, this study reveals only the visible part of an iceberg and 
suggests that the immersed part must be further investigated.
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